Anti-c-myc RNAi-Based Onconanotherapeutics

Area of Science:

• Oncology
• Molecular Biology
• Nanotechnology

Background:

• The c-myc proto-oncogene is overexpressed in most human cancers, making it a key therapeutic target.
• Inhibiting c-myc expression has demonstrated significant anti-cancer effects in early studies.
• RNA interference (RNAi) offers a mechanism for targeted gene silencing, presenting a potential strategy for c-myc inhibition.

Purpose of the Study:

• To review anti-c-myc RNAi-based nanosystems developed between 2005 and 2020.
• To highlight the role of nanoparticle carriers in delivering RNAi effectors for c-myc gene silencing.
• To assess the clinical viability of RNAi-based platforms for cancer treatment.

Main Methods:

• Review of scientific literature focusing on RNAi-based anti-c-myc therapies.
• Analysis of studies utilizing various nanoparticles (organic and inorganic) as carriers for small interfering RNA (siRNA), DICER-substrate siRNA (DsiRNA), and short hairpin RNA (shRNA) expression plasmids.
• Evaluation of in vitro and in vivo assessments of these nanosystems.

Main Results:

• Nanoparticles have been extensively investigated as carriers for anti-c-myc RNAi agents.
• Diverse RNAi effectors, including siRNA, DsiRNA, and shRNA, have been employed.
• Both organic and inorganic nanoparticles show potential for delivering these agents.

Conclusions:

• RNAi-based nanosystems represent a promising avenue for developing novel anti-cancer therapeutics targeting c-myc.
• The design and efficacy of nanoparticle carriers are critical for the clinical success of anti-c-myc RNAi strategies.
• Continued research in this area holds potential for broadly applicable and effective cancer treatments.